Back to top

Is AcelRx Pharmaceuticals (ACRX) Outperforming Other Medical Stocks This Year?

Read MoreHide Full Article

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. AcelRx Pharmaceuticals (ACRX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of ACRX and the rest of the Medical group's stocks.

AcelRx Pharmaceuticals is a member of the Medical sector. This group includes 758 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ACRX is currently sporting a Zacks Rank of #2 (Buy).

Over the past three months, the Zacks Consensus Estimate for ACRX's full-year earnings has moved 7.42% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

Based on the latest available data, ACRX has gained about 50.62% so far this year. In comparison, Medical companies have returned an average of 4.74%. This means that AcelRx Pharmaceuticals is performing better than its sector in terms of year-to-date returns.

Breaking things down more, ACRX is a member of the Medical - Drugs industry, which includes 163 individual companies and currently sits at #162 in the Zacks Industry Rank. Stocks in this group have gained about 3.59% so far this year, so ACRX is performing better this group in terms of year-to-date returns.

Going forward, investors interested in Medical stocks should continue to pay close attention to ACRX as it looks to continue its solid performance.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


AcelRx Pharmaceuticals, Inc. (ACRX) - free report >>

More from Zacks Tale of the Tape

You May Like